首页> 外文期刊>International Journal of Radiation Oncology, Biology, Physics >Reirradiation of locally recurrent nasopharynx cancer with external beam radiotherapy with or without brachytherapy.
【24h】

Reirradiation of locally recurrent nasopharynx cancer with external beam radiotherapy with or without brachytherapy.

机译:伴或不伴近距离放射治疗的外部束放射疗法对局部复发性鼻咽癌的再照射。

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: To determine survival rates of patients with locally recurrent nasopharynx cancer (LRNPC) treated with modern therapeutic modalities. METHODS AND MATERIALS: From July 1996 to March 2008, 29 patients were reirradiated for LRNPC. Thirteen patients received combined-modality treatment (CMT), consisting of external beam radiotherapy (EBRT) followed by intracavitary brachytherapy, whereas 16 received EBRT alone. The median age was 50 years, 59% were male, 38% were Asian, 69% had World Health Organization Class III histology, and 86% were treated for their first recurrence. Nine, 6, 8, and 6 patients had recurrent Stage I, II, III, and IV disease, respectively. Patients in the EBRT-alone group had more advanced disease. Median time to reirradiation was 3.9 years. In total, 93% underwent imaging with positron emission tomography and/or magnetic resonance imaging before reirradiation, 83% received intensity-modulated radiotherapy, and 93% received chemotherapy, which was platinum-based in 85% of cases. RESULTS: The median follow-up for all patients was 45 months and for surviving patients was 54 months. Five-year actuarial local control, event-free survival, and overall survival rates were 52%, 44%, and 60%, respectively. No difference was observed between patients treated with EBRT or CMT. Overall survival was superior in patients who achieved local control (p = 0.0003). The incidence of late Grade > or =3 events in patients re-treated with EBRT alone was significantly increased compared with those receiving CMT (73% vs. 8%; p = 0.005). CONCLUSIONS: In this modern reirradiation series of patients with LRNPC, favorable overall survival compared with historical series was achieved. Patients treated with CMT experienced significantly fewer severe late effects compared with those treated with EBRT.
机译:目的:确定采用现代治疗方法治疗的局部复发性鼻咽癌(LRNPC)患者的生存率。方法和材料:从1996年7月到2008年3月,有29例患者再次接受LRNPC照射。 13例患者接受了联合方式治疗(CMT),包括体外放射治疗(EBRT)和腔内近距离放射治疗,而16例仅接受了EBRT。中位年龄为50岁,男性为59%,亚洲人为38%,世界卫生组织III级组织学为69%,首次复发接受治疗的比例为86%。分别有9名,6名,8名和6名患者复发了I,II,III和IV期疾病。仅EBRT组的患者患有更晚期的疾病。再照射的中位时间为3.9年。总的来说,有93%的患者在重新照射前接受了正电子发射断层扫描和/或磁共振成像,其中83%的患者接受了调强放射治疗,而93%的患者接受了化疗,其中有85%的患者采用了铂类药物。结果:所有患者的中位随访时间为45个月,存活患者的中位随访时间为54个月。五年精算局部控制,无事件生存率和总生存率分别为52%,44%和60%。在接受EBRT或CMT治疗的患者之间未观察到差异。达到局部控制的患者的总体生存率更高(p = 0.0003)。与接受CMT的患者相比,仅接受EBRT再治疗的患者晚期或≥3级事件的发生率显着增加(73%比8%; p = 0.005)。结论:在这个现代的LRNPC患者再照射系列中,与历史系列相比,获得了良好的总体存活率。与使用EBRT治疗的患者相比,接受CMT治疗的患者的严重晚期效应明显更少。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号